PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy

Yu,Wen; Cao,Dedong; Zhou,Hao; Hu,Yu; Guo,Tao

doi:10.3892/or.2015.3809

PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy

Authors:
- Wen Yu
- Dedong Cao
- Hao Zhou
- Yu Hu
- Tao Guo
View Affiliations

Affiliations: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430000, P.R. China, Institute of Cancer, Renmin Hospital of Wuhan University, Wuhan University, Wuhan, Hubei 430000, P.R. China
Published online on: February 17, 2015 https://doi.org/10.3892/or.2015.3809
Pages: 2086-2092

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between hyperglycemia and outcomes during chemotherapy has been reported in several tumors, including multiple myeloma (MM). However, the underlying mechanism of how hyperglycemia affects the survival of MM cells during chemotherapy remain to be elucidated. MM cells were cultured in 10 mM glucose with or without chemotherapeutic agents. Following treatment of MM cells with dexamethasone or bortezomib, an MTT assay was used to evaluate the toxicity of dexamethasone or bortezomib on cell proliferation, and changes of reactive oxygen species (ROS) level were detected by flow cytometry (FCM) analysis. Small interference RNA (siRNA) was applied to inhibit the expression of peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α). Expressions of PGC-1α and antioxidant factors such as superoxide dismutase 2 (SOD‑2), glutathione peroxidase 1 (GPX-1), and catalase (CAT) were measured by RT-PCR prior to and following treatment. The results showed that the level of PGC-1α in MM cells cultured in high-glucose medium was upregulated prior to and following treatment of chemotherapeutic agents, and these cells showed less fold-change of ROS after insult of drugs, when compared to the control. Genes encoding antioxidant factors such as SOD-2 and CAT were also upregulated. Inhibition of PGC-1α enhanced the toxicity of antitumor agents, associated with reduced expression of antioxidant factors, and elevated level of ROS. The present findings suggested that hyperglycemia may influence the anticancer effect of chemotherapeutic agents in MM by upregulating the expression of PGC-1α and associated antioxidant factors. Inhibition of PGC-1α or control of hyperglycemia may be beneficial in improving the efficacy of chemotherapy in MM patients with diabetes.

View Figures

View References

1	Guglielmelli T and Palumbo A: Incorporating novel agents in the management of elderly myeloma patients. Curr Hematol Malig Rep. 8:261–269. 2013. View Article : Google Scholar : PubMed/NCBI
2	Palumbo A and Mina R: Management of older adults with multiple myeloma. Blood Rev. 27:133–142. 2013. View Article : Google Scholar : PubMed/NCBI
3	Chou YS, Yang CF, Chen HS, et al: Pre-existing diabetes mellitus in patients with multiple myeloma. Eur J Haematol. 89:320–327. 2012. View Article : Google Scholar : PubMed/NCBI
4	Issa ZA, Zantout MS and Azar ST: Multiple myeloma and diabetes. ISRN Endocrinol. 2011:8150132011.
5	Jung SH, Jang HC, Lee SS, et al: The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. Biomed Res Int. 2014:4131492014. View Article : Google Scholar : PubMed/NCBI
6	Ahmed YA and Eltayeb A: Clinical challenges: myeloma and concomitant type 2 diabetes. Int J Hematol Oncol Stem Cell Res. 7:34–41. 2013.
7	Wu W, Merriman K, Nabaah A, et al: The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 111:628–636. 2014. View Article : Google Scholar : PubMed/NCBI
8	Chiu BC, Gapstur SM, Greenland P, Wang R and Dyer A: Body mass index, abnormal glucose metabolism, and mortality from hematopoietic cancer. Cancer Epidemiol Biomarkers Prev. 15:2348–2354. 2006. View Article : Google Scholar : PubMed/NCBI
9	Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes. 40:405–412. 1991. View Article : Google Scholar : PubMed/NCBI
10	Busik JV, Mohr S and Grant MB: Hyperglycemia-induced reactive oxygen species toxicity to endothelial cells is dependent on paracrine mediators. Diabetes. 57:1952–1965. 2008. View Article : Google Scholar : PubMed/NCBI
11	Zorov DB, Juhaszova M and Sollott SJ: Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 94:909–950. 2014. View Article : Google Scholar : PubMed/NCBI
12	Edeas M: Strategies to target mitochondria and oxidative stress by antioxidants: key points and perspectives. Pharm Res. 28:2771–2779. 2011. View Article : Google Scholar : PubMed/NCBI
13	Vurusaner B, Poli G and Basaga H: Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med. 52:7–18. 2012. View Article : Google Scholar
14	Valle I, Alvarez-Barrientos A, Arza E, Lamas S and Monsalve M: PGC-1alpha regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res. 66:562–573. 2005. View Article : Google Scholar : PubMed/NCBI
15	Nishikawa T, Edelstein D, Du XL, et al: Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404:787–790. 2000. View Article : Google Scholar : PubMed/NCBI
16	Finck BN and Kelly DP: PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest. 116:615–622. 2006. View Article : Google Scholar : PubMed/NCBI
17	Cao D, Zhou H, Zhao J, et al: PGC-1α integrates glucose metabolism and angiogenesis in multiple myeloma cells by regulating VEGF and GLUT-4. Oncol Rep. 31:1205–1210. 2014.PubMed/NCBI
18	St-Pierre J, Drori S, Uldry M, et al: Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell. 127:397–408. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kong X, Wang R, Xue Y, et al: Sirtuin 3, a new target of PGC-1 alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One. 5:e117072010. View Article : Google Scholar
20	Fujisawa K, Nishikawa T, Kukidome D, et al: TZDs reduce mitochondrial ROS production and enhance mitochondrial biogenesis. Biochem Biophys Res Commun. 379:43–48. 2009. View Article : Google Scholar
21	Zhang LN, Zhou HY, Fu YY, et al: Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 62:1297–1307. 2013. View Article : Google Scholar :
22	Pearce EL, Walsh MC, Cejas PJ, et al: Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature. 460:103–107. 2009. View Article : Google Scholar : PubMed/NCBI
23	Villarreal-Garza C, Shaw-Dulin R, Lara-Medina F, et al: Impact of diabetes and hyperglycemia on survival in advanced breast cancer patients. Exp Diabetes Res. 2012:7320272012. View Article : Google Scholar : PubMed/NCBI
24	Luo J, Chen YJ and Chang LJ: Fasting blood glucose level and prognosis in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 76:242–247. 2012. View Article : Google Scholar
25	Friday E, Ledet J and Turturro F: Response to dexamethasone is glucose-sensitive in multiple myeloma cell lines. J Exp Clin Cancer Res. 30:812011. View Article : Google Scholar : PubMed/NCBI
26	Scarpulla RC, Vega RB and Kelly DP: Transcriptional integration of mitochondrial biogenesis. Trends Endocrinol Metab. 23:459–466. 2012. View Article : Google Scholar : PubMed/NCBI
27	Sheean PM, Kilkus JM, Liu D, Maciejewski J and Braunschweig CA: Incident hyperglycemia, parenteral nutrition administration and adverse outcomes in patients with myeloma admitted for initial auto-SCT. Bone Marrow Transplant. 48:1117–1122. 2013. View Article : Google Scholar : PubMed/NCBI
28	McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST and Shanmugam M: Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood. 119:4686–4697. 2012. View Article : Google Scholar : PubMed/NCBI
29	Zhao Y, Butler EB and Tan M: Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 4:e5322013. View Article : Google Scholar : PubMed/NCBI
30	Gitenay D, Wiel C, Lallet-Daher H, et al: Glucose metabolism and hexosamine pathway regulate oncogene-induced senescence. Cell Death Dis. 5:e10892014. View Article : Google Scholar : PubMed/NCBI
31	Zhao Y, Liu H, Riker AI, et al: Emerging metabolic targets in cancer therapy. Front Biosci (Landmark Ed). 16:1844–1860. 2011. View Article : Google Scholar
32	DeBerardinis RJ, Mancuso A, Daikhin E, et al: Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 104:19345–19350. 2007. View Article : Google Scholar : PubMed/NCBI
33	Zhao Y, Altman BJ, Coloff JL, et al: Glycogen synthase kinase 3alpha and 3beta mediate a glucose-sensitive antiapoptotic signaling pathway to stabilize Mcl-1. Mol Cell Biol. 27:4328–4339. 2007. View Article : Google Scholar : PubMed/NCBI
34	Danial NN, Gramm CF, Scorrano L, et al: BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 424:952–956. 2003. View Article : Google Scholar : PubMed/NCBI
35	Rathmell JC, Fox CJ, Plas DR, Hammerman PS, Cinalli RM and Thompson CB: Akt-directed glucose metabolism can prevent Bax conformation change and promote growth factor-independent survival. Mol Cell Biol. 23:7315–7328. 2003. View Article : Google Scholar : PubMed/NCBI
36	Mathupala SP, Ko YH and Pedersen PL: Hexokinase II: cancer’s double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 25:4777–4786. 2006. View Article : Google Scholar : PubMed/NCBI
37	Gendron MC, Schrantz N, Metivier D, et al: Oxidation of pyridine nucleotides during Fas- and ceramide-induced apoptosis in Jurkat cells: correlation with changes in mitochondria, glutathione depletion, intracellular acidification and caspase 3 activation. Biochem J. 353:357–367. 2001. View Article : Google Scholar : PubMed/NCBI
38	Vu K, Busaidy N, Cabanillas ME, et al: A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 12:355–362. 2012. View Article : Google Scholar : PubMed/NCBI
39	Puigserver P, Wu Z, Park CW, Graves R, Wright M and Spiegelman BM: A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell. 92:829–839. 1998. View Article : Google Scholar : PubMed/NCBI
40	Kang C and Li Ji L: Role of PGC-1α signaling in skeletal muscle health and disease. Ann NY Acad Sci. 1271:110–117. 2012. View Article : Google Scholar
41	Radak Z, Zhao Z, Koltai E, Ohno H and Atalay M: Oxygen consumption and usage during physical exercise: the balance between oxidative stress and ROS-dependent adaptive signaling. Antioxid Redox Signal. 18:1208–1246. 2013. View Article : Google Scholar :
42	Wenz T: Regulation of mitochondrial biogenesis and PGC-1α under cellular stress. Mitochondrion. 13:134–142. 2013. View Article : Google Scholar : PubMed/NCBI
43	Salem AF, Whitaker-Menezes D, Howell A, Sotgia F and Lisanti MP: Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle. 11:4174–4180. 2012. View Article : Google Scholar : PubMed/NCBI
44	Tennakoon JB, Shi Y, Han JJ, et al: Androgens regulate prostate cancer cell growth via an AMPK-PGC-1α-mediated metabolic switch. Oncogene. 33:5251–5261. 2014. View Article : Google Scholar
45	Girnun GD: The diverse role of the PPARγ coactivator 1 family of transcriptional coactivators in cancer. Semin Cell Dev Biol. 23:381–388. 2012. View Article : Google Scholar : PubMed/NCBI